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Abstract
Background: Information is limited regarding the knowledge and attitudes of physicians
typically involved in the referral of patients for implantable cardioverter-defibrillator (ICD)
implantation.
Methods: We conducted a survey of primary care physicians and cardiologists at the Univer-
sity of Rochester Medical Center and the Unity Health System Rochester, NY from December
2008 to February 2009. The survey collected information regarding physicians’ knowledge of
and attitudes towards ICD therapy.
Results: Of the 332 surveys distributed, 110 (33%) were returned. Over-all 94 (87%) physi-
cians reported referring patients for ICD implantation. Eighteen (17%) physicians reported
unawareness of guidelines for ICD use. Sixty-four (59%) physicians recommended ICD in
patients with ischemic cardiomyopathy and left ventricular ejection fraction (LVEF) £ 35%.
Sixty-five (62%) physicians use £ 35% as the LVEF criterion for ICD referral in patients with
non-ischemic cardiomyopathy. Cardiologists were more familiar than primary care physicians
with LVEF criteria for implantation of ICD in patients with ischemic and non-ischemic
cardiomyopathy (p value 0.005 and 0.002, respectively). Twenty-nine (27%) participants were
unsure regarding the benefits of ICDs in eligible women and blacks. Eighty two (76%) physi-
cians believed that an ICD could benefit patients ≥ 70 years old, whereas only 53 (49%)
indicated that an ICD would benefit patients ≥ 80.
Conclusions: A lack of familiarity with current clinical guidelines regarding ICD implanta-
tion exists. Primary care physicians are less aware of clinical guidelines than are cardiolo-
gists. This finding highlights the need to improve the dissemination of guidelines to primary
care physicians in an effort to improve ICD utilization. (Cardiol J 2010; 17, 3: 267–273)
Key words: implantable cardioverter-defibrillator, physician’s knowledge,
gender and racial disparities
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Introduction
Cardiovascular disease (CVD) continues to be
the leading cause of death in developed countries,
with sudden cardiac death (SCD) accounting for
approximately 50% of all cardiovascular deaths [1, 2].
Patients with significant coronary artery disease
(CAD), left ventricular systolic dysfunction and pri-
or ventricular tachyarrhythmias are at particularly
high risk for SCD [3, 4]. Compared to optimal me-
dical therapy, implantable cardioverter-defibrillators
(ICD) have been consistently more efficacious in
preventing SCD in patients with ischemic and non-
-ischemic cardiomyopathy [5–9]. The most recent
guidelines issued by the American College of Car-
diology and the American Heart Association (ACC/
/AHA) [10] recommend the implantation of an ICD
for primary prevention of SCD in patients with is-
chemic and non-ischemic cardiomyopathy, a left
ventricular ejection fraction (LVEF) of 35% or less,
and New York Heart Association (NYHA) Class II
or Class III heart failure symptoms.
Research has highlighted the under-utilization
and inequality in the distribution of ICDs among
eligible patients [11–13]. Little is known about phy-
sicians’ knowledge and attitudes towards ICD the-
rapy. Since the recommendation of a physician can
greatly influence a patient’s decision regarding ICD
implantation, it is critical to gain a better under-
standing of physicians’ knowledge and attitudes
regarding this life-saving technology. The aim of our
project was to evaluate knowledge and attitudes of
physicians regarding ICD therapy using an original
survey instrument. We hypothesized that a lack of
knowledge exists among physicians who are in-
volved in the referral of eligible patients for ICD
implantation.
Methods
The survey was developed integrating informa-
tion from a literature review, the ACC/AHA guide-
lines regarding ICD therapy, and by consensus
among the investigators. To improve the content
validity of the survey, the initial draft  was distri-
buted to a sample multi-disciplinary team of physi-
cians. The critical appraisal of the sample facilitat-
ed revision for clarity and reliability. The first items
in the instrument assessed self-reported awareness
of guidelines, as physicians were asked if they were
aware of clinical guidelines regarding ICD implan-
tation with a Yes/No question. Their knowledge of
the guidelines was further explored by questions
regarding LVEF criteria determining ICD eligibili-
ty in patients with both ischemic and non-ischemic
cardiomyopathy.
The next part of the survey was a series of
questions to ascertain physicians’ attitudes regard-
ing ICDs, scored on a 5-point Likert scale, includ-
ing if ICDs prolong life, prevent SCD, are benefi-
cial in women, blacks, and in patients aged ≥ 70 and
≥ 80. We chose this age limit because less published
data exists regarding ICDs in the older patient pop-
ulation. Other questions asked if ICDs are cost-ef-
fective and improve quality of life, as well as if they
had any concerns regarding manufacturing defects
and recalls. In addition to these questions, three
clinical scenarios, also included in the survey, cap-
tured physicians’ knowledge regarding appropriate
ICD referral criteria. All three scenarios met the
ACC/AHA Class I indication for ICD implantation.
Finally, the survey asked about personal demo-
graphics and practice characteristics. Space was
provided for physician comments regarding any fac-
tors that they perceived as potential barriers to ap-
propriate ICD implantation dissemination. The in-
stitutional review board approval was obtained be-
fore mailing the survey to physicians.
The original survey instrument was designed
to obtain cross-sectional data regarding physicians’
knowledge and attitudes toward ICDs. In practice,
eligible patients are typically identified by their pri-
mary care physician and/or cardiologist and are sub-
sequently referred to an electrophysiologist for the
ICD implantation.
Thus, physicians in the cardiology, general in-
ternal medicine, hospitalist and family medicine
specialties were chosen for the study. The study
was conducted at the University of Rochester Med-
ical Center and the Unity Health System, Roches-
ter NY, giving both a university and a community-
based hospital setting. Reminder mailings were
sent to non-responders three weeks following the
initial mailing.
Statistical analysis
Descriptive statistics were used to describe the
frequency of physicians’ awareness of guidelines,
both self reported and objectively by analyzing their
knowledge of LVEF criteria. A participant’s demo-
graphic and attitudes to ICDs were described us-
ing frequency analysis. The c2 and Fisher’s exact
tests were used to evaluate the associations be-
tween the awareness of guidelines and demographic
characteristics as appropriate. Multivariable logis-
tic regression was used to evaluate factors that may
predict ICD referral. We designed three separate
models, using the physicians’ responses (Yes/No)
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to three case scenarios potentially requiring refer-
ral for an ICD.
The independent variables evaluated in the lo-
gistic regression model were physicians’ knowledge
of current guidelines and beliefs regarding the ef-
fect of the ICDs in: prolonging life; benefits in wom-
en; benefits in blacks; improve quality of life; cost
effective or not; age of physician; gender; years
since medical school (< 20 or > 20 years); and spe-
cialty. The barriers to ICD dissemination as report-
ed by study participants were categorized accord-
ing to patient level, physician level and system/ad-
ministrative level.
All the statistical analyses were performed
using SAS 9.2 software. A p value < 0.05 was con-
sidered significant.
Results
Characteristics of the respondents
and distribution of knowledge
Respondent demographics, awareness of clin-
ical guidelines and LVEF cut-off criteria used by the
physicians for referral of ICD implantation are
shown in Table 1. Seventy-seven (70%) physicians
were under 50 years of age and 57 (52%) graduated
from medical school in the last 20 years. Ninety-
four (87%) physicians reported that they refer pa-
tients to cardiovascular specialists for consideration
of an ICD implantation. Eighteen (17%) physicians
reported unawareness of the ACC/AHA clinical
guidelines for ICD implantation. Eighty-seven
(79%) physicians recommended an ICD for ‘Case A’,
a 45-year-old woman with non-ischemic cardiomyo-
pathy and LVEF 30%. Eighty-one (74%) physicians
recommended ICD for ‘Case B’, a 72-year-old man
with ischemic cardiomyopathy and LVEF 25%.
Fifty-four (50%) physicians recommended an ICD
for ‘Case C’,  an 81-year-old man with ischemic car-
diomyopathy and LVEF 30–35%.
Factors associated with physicians’
knowledge and attitudes
Knowledge regarding the current LVEF crite-
rion for ICD implantation in individuals with is-
chemic cardiomyopathy was significantly higher
among cardiologists as compared to primary care
physicians (OR [odds ratio] 3.1; 95% CI [confidence
interval] 1.3–7.0). A similar association was seen
for knowledge of LVEF criteria for non-ischemic
cardiomyopathy patients (OR 3.8; 95% CI 1.5–9.4).
Physicians younger than 50 were significantly more
likely to know the clinical guidelines for non-is-
chemic cardiomyopathy patients (OR 3.4; 95% CI
1.4–8.2) with no difference in knowledge for LVEF
criteria for ischemic cardiomyopathy patients (OR
2.1; 95% CI 0.9–4.9). The reported knowledge of
current guidelines did not correlate with years from
medical school graduation (< 20 vs > 20 years), for
ischemic cardiomyopathy, (OR 1.18; 95% CI 0.5–2.5)
and for non-ischemic cardiomyopathy (OR 1.54;
95% CI 0.6–3.4). Similarly, no association was found
between knowledge and physicians of different gen-
der (OR 0.7; 95% CI 0.3–1.9, OR 0.8; 95% CI 0.3–2.1)
for ischemic and non-ischemic cardiomyopathy re-
spectively.
The beliefs and attitudes of physicians regard-
ing ICD therapy are summarized in Table 2. Nine-
ty four (85%) physicians believed that ICD use pro-
longs life, and 104 (96%) agreed that ICDs can pro-
tect from SCD. Twenty-nine (27%) physicians
either believed that ICDs have less benefit in wom-
en and blacks or were unsure. Fifteen (14%) physi-
cians reported concerns regarding manufacturing
recalls and defects, indicating that such belief could
play an important role in referral for ICD implanta-
tion. Eighty-two (75%) physicians agreed that an
ICD would not improve patients’ quality of life.
Table 1. Demographic characteristics, aware-
ness of clinical guidelines and left ventricular
ejection fraction (LVEF) cut-off criteria used
by physicians for referral of implantable
cardioverter-defibrillator (ICD) implantation.
Parameters Frequency Percentage
Age:
£ 50 77 70%
> 50 33 30%
Gender:
Male 85 78%
Female 24 22%
Specialty:
Primary care 64 58%
Cardiology 46 42%
Years since medical
school graduation:
£ 20 57 52%
> 20 53 48%
Physicians currently 94 87%
refer patients for ICD
LVEF cut-off criteria:
Ischemic cardiomyopathy:
£ 30% 45 41%
£ 35% 64 59%
Non-ischemic
cardiomyopathy:
£ 30% 39 37%
£ 35% 65 62%
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While 82 (76%) physicians reported that ICDs can
be beneficial in patients older than 70, only 53 (49%)
believed that an ICD would be an effective therapy
in patients 80 years and older. Sixty-two (59%) phy-
sicians considered an ICD to be a cost-effective
treatment.
The difference between cardiologists’ and pri-
mary care physicians’ attitudes towards an ICD
therapy among women, blacks, patients ≥ 70 and
≥ 80 years of age is shown in Figure 1.
Is knowledge of the ACC/AHA guidelines
related to ICD referral?
The self-reported awareness of ICD clinical
guidelines by physicians was significantly associat-
ed with ICD referral (OR 8; 95% CI 2.4–30). The
knowledge of LVEF criteria for non-ischemic cardio-
myopathy was not associated with recommendation
of ICD for Case A (a patient with non-ischemic car-
diomyopathy; OR 2.1; 95% CI 0.8–5.6). However,
the knowledge of LVEF criteria for ischemic cardio-
myopathy was significantly associated with recom-
mendation of ICD for Cases B and C (patients with
ischemic cardiomyopathy; OR 3.6; 95% CI 1.4–8.8
and OR 6.1; 95% CI 2.6–14.5, respectively).
Factors associated with referral of ICD
The variables found to be significantly associa-
ted with referral after inclusion in multivariate lo-
gistic regression models for the three clinical
scenarios are summarized in Table 3.
The perception of ‘cost-effectiveness’ of ICD
was strongly associated with ICD referral when
physicians were presented with Case A. The cardio-
logists were more likely to recommend this patient
for an ICD therapy as compared to primary care
physicians. The perception that ‘ICD benefits pa-
tients 70 years and older’ was an independent pre-
dictor of referral for ICD in Case B. In Case C, phy-
sicians younger than 50 years of age were more like-
ly to refer for ICD as compared to physicians > age
50. The perception that ‘ICD benefits patients 80
and older’ was also significantly associated with
recommending an ICD for this patient.
The reported potential barriers to appropriate
ICD utilization as reported by study participants are
summarized in Table 4.
Table 2. Frequency distribution of knowledge and attitudes regarding implantable cardioverter-
-defibrillator (ICD) use.
Strongly Somewhat Neutral Somewhat Strongly
disagree  disagree  agree  agree
ICDs prolong life 2 (2%) 3 (3%) 9 (8%) 38 (35%) 56 (52%)
ICDs prevent sudden cardiac death 2 (2%) 0 (0%) 3 (3%) 29 (27%) 75 (69%)
Women benefit equally from ICDs 0 (0%) 5 (5%) 24 (22%) 35 (33%) 43 (40%)
compared to men
Blacks benefit equally from ICDs 0 (0%) 5 (5%) 24 (22%) 33 (30%) 46 (43%)
compared to whites
ICDs improve quality of life 13 (12%) 20 (18%) 49 (45%) 19 (18%) 7 (6%)
Reported manufacturing defects 30 (28%) 34 (32%) 26 (25%) 13 (12%) 2 (2%)
influence ICD referral
ICDs are cost-effective 2 (2%) 13 (12%) 29 (27%) 40 (38%) 22 (21%)
ICDs benefit patients older than 1 (0.9%) 7 (6%) 18 (17%) 45 (42%) 37 (34%)
70 years of age
ICDs benefit patients older than 4 (4%) 19 (17%) 32 (30%) 41 (38%) 12 (11%)
80 years of age
Figure 1. Percentage of cardiologist vs primary care
physician who agree that implantable cardioverter-defi-
brillator therapy benefits women, blacks, patients abo-
ve 70 and above 80 years of age.
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Discussion
This study provides a unique opportunity to
evaluate the current state of physicians’ knowledge
and attitudes regarding the use of ICDs in their
patients. The results show that most physicians
were aware of the presence of ACC/AHA guidelines
for ICD implantation. Knowledge of these guide-
lines is also associated with reported referral pat-
terns. However, actual knowledge is less robust
when physicians are challenged with more detailed
questions regarding clinical guidelines, for exam-
ple, their knowledge regarding the LVEF criterion
for eligibility of patients for an ICD with ischemic
or non-ischemic cardiomyopathy. As expected, car-
diologists are more aware of the ICD implantation
guidelines than are primary care physicians. How-
ever, there was no difference between younger
physicians (£ 50) and those who graduated from
medical school within the last 20 years, compared
to physicians > 50 and those who graduated from
medical school more than 20 years ago in their
awareness of the current guidelines. Although most
physicians know that ICDs prevent SCD, more than
25% remain unsure regarding the benefits of ICDs
in women and blacks. This data suggests that, al-
though many physicians are aware of the current
guidelines, their knowledge is insufficient to prompt
them to refer all of those individuals who can ben-
efit from this life-saving therapy.
Several potential factors may explain the lack
of up-to-date knowledge among physicians, espe-
cially in primary care [14]. Busy practice patterns
and perception of primary care physicians regard-
ing their role in the referral of devices seem the
most important. Primary care physicians provide
clinical care for a vast range of clinical issues that
go beyond cardiovascular diseases [15]. For these
busy practitioners, keeping up with the most cur-
rent clinical research and guidelines seems a daunt-
ing task.
In our study, 25% of physicians were general-
ly unclear regarding the benefits of ICD in women
and blacks. This uncertainty may further contri-
bute to the disparities observed in the use of ICDs.
The lack of clear clinical evidence regarding bene-
fits of ICD in these sub-groups of patients may be
one of the important factors contributing to these
attitudes. In the clinical trials evaluating the bene-
fits of ICDs, the participation of women and racial
minorities has traditionally been low, compromis-
ing the generalizability of results. For example, men
composed 92% of the individuals in MADIT I, 86%
in MUSTT, and 84% in MADIT II [5–7]. Although
sub-group analyses from some of these studies have
shown mixed results on the efficacy of ICD among
women as compared to men, the results of these
analyses should be interpreted with caution given
Table 3. Logistic regression of selected model
variables on implantable cardioverter-defibrilla-
tor (ICD) referral.
Variable Odds 95% p
ratio confidence
interval
Case A
Specialty (cardiology 3.67 1.11–12.05 0.032
vs non-cardiology)
ICDs are cost-effective 2.79 1.01–7.68 0.047
Case B
ICDs benefit patients 4.00 1.52–10.49 0.004
older than 70 years
of age
Case C
Physician age (< 50 0.31 0.11–0.87 0.027
vs > 50 years old)
ICDs benefit patients 6.49 2.57–16.40 0.0001
older than 80 years
of age
Table 4. Barriers for dissemination of implantable
cardioverter-defibrillators as reported by the
physicians (total n = 30).
Characteristics N (%)
Patient characteristics
Function status 1 (3)
Cognitive function/dementia 3 (10)
Presence of multiple co-morbidities 5 (17)
Reluctance/preferences 5 (17)
Concerns over device recalls 1 (3)
Age 1 (3)
Compliance 1 (3)
Language barriers 1 (3)
Physician characteristics
Lack of familiarity with referral process 1 (3)
Lack of system support for identification 1 (3)
of eligible patients
Concerns regarding 2 (7)
inappropriate shocks
Concerns regarding cost of devices 7 (23)
Concerns regarding effects 2 (7)
on quality of life
System-based — insurance 3 (10)
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the small sample size and subsequently limited sta-
tistical power [16, 17]. The literature supporting the
benefits of ICD among blacks also has been mixed.
In the sub-study from MADIT II, ICD implantation
was associated with reduced total mortality, cardi-
ac death, and SCD in whites but not in blacks [18].
In the MUSTT trial, blacks did not benefit from ICD
as did whites [19]. In fact blacks in MUSTT had
a better response to anti-arrhythmic medications at
electrophysiology testing and lower acceptance rate
to ICD implantation compared to whites, something
that led to a lower rate of ICD implantation. These
issues may have confounded the results showing
a lack of benefit in the MUSTT population. In con-
trast SCD-HeFT trial found an equal reduction in
mortality among both racial groups (hazard ratio
0.65 in blacks and 0.73 in whites) [20]. The ACC/
/AHA clinical guidelines recommend ICD use for
all eligible patients from all racial/ethnic origins who
meet the criteria for ICD implantation.
The cost of devices emerged as one of the fac-
tors that physicians perceive as a barrier for the
dissemination of ICD, and it was also an important
predictor of ICD referral. Numerous studies have
evaluated the cost-effectiveness of ICD use [21, 22].
The results from these studies are quite varied as the
analyses depend on cost estimates, projected follow-
up care, and differing assumptions regarding treat-
ment effects. In a cost effectiveness analysis based
on the MADIT II population, the incremental cost-
-effectiveness ratio was $235,000 per year of life saved,
unadjusted for quality of life [21]. The cost-effective-
ness approached $50,000 to $100, 000 when the data
was extrapolated to 12 years. This analysis was limit-
ed by the short trial duration and hence the treatment
effects in future were estimated. Ideally, cost-benefit
analyses regarding ICD use should include a person’s
remaining years of life. The complexities of cost-ef-
fectiveness determination and the resulting contro-
versy and confusion among physicians may explain the
concerns of participants in our study.
The age of the patients, presence of co-mor-
bidities and impact of ICD use on quality of life were
other important factors that physicians reported as
potential factors that may affect ICD referral. Sig-
nificantly fewer physicians would consider ICD in
patients aged 80 and above. Although there are no
clear ‘age limits’ prescribed in the clinical guide-
lines, ICD is not recommended in patients with
severe co-morbidities and expected survival of less
than one year. The literature supports the use of
ICD in older patients as data has shown that patients
75 and older derive equal benefits for prevention of
SCD as do younger patients [23]. Thus, age should
be considered in the light of severe co-morbidities,
cognitive function and functional status. Physicians
should communicate with patients and family mem-
bers regarding potential benefits, risks and alter-
natives of ICD treatment.
ICDs have no role in improving quality of life,
but previous reports have suggested that ICD thera-
py may be associated with reduced psychological
functioning and reduced quality of life [24, 25]. In
a recently published report from a large primary
prevention population, ICD therapy was not asso-
ciated with any detectable adverse quality of life ef-
fects during 30 months of follow-up but the ICD
shocks were associated with decreased quality of
life [26]. The results from previous reports on ICD
and quality of life may not be applicable to current
patients, as significant advances have occurred in
the devices and implantation techniques. The cur-
rently available devices are much smaller and are
implanted transvenously rather than via open chest
implantation. Further efforts should focus on design-
ing new ICD algorithms to minimize inappropriate
shocks and thus improve the tolerability of devices.
Adequate support should be provided to patients who
receive ICD shocks to minimize any adverse effects
on psychological or physical functioning.
In summary, our project provides a description
of the knowledge, attitudes, and practices of primary
care providers and cardiologists regarding the use
of ICDs. Since the knowledge of practice guidelines
is associated with ICD referral, there may be a need
for development of well-structured educational pro-
grams to improve the referral rates to more appro-
priate levels based on current evidence. Improving
the familiarity of physicians with current guidelines
would help incorporate ‘evidence-based care’ in their
clinical practice and reduced variability in the deli-
very of care across different groups of eligible patients.
Our study has a number of limitations. The
greatest is a relatively small sample size. The sam-
ple does, however, represent a diverse group of
physicians practicing cardiology and internal medi-
cine affiliated with university and community-based
hospitals. Moreover, the data suggests the need for
studies with more substantial multi-center samples.
Some other potential limitations of the study include
respondent’s recall and response rate. Our study
included only three clinical scenarios, so the results
may not be applicable to other clinical situations.
Conclusions
Our study highlights some of the important
factors that may play an influential role in referral
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of patients for ICD implantation, including the cost
of devices, area of specialty, age of patients, and age
of physicians. There is a need not only to improve
current knowledge of physicians who may need to
refer patients for ICD implantation but also to re-
duce ‘grey areas’ in the evidence supporting the use
of these life-saving devices.
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